银屑病新药-阿普斯特

(apremilast) is a phosphodiesterase-4 inhibitor developed by the American company Celgene. Its mechanism of action is to increase adenosine phosphate by regulating the expression of phosphodiesterase-4 in immune cells, thereby inhibiting immune and inflammatory responses. In 2014, the drug was first approved for marketing in the United States under the trade name Otezla. It was the first oral preparation approved by the FDA for the treatment of plaque psoriasis (psoriasis) and psoriatic arthritis.

In 2014, the FDA approved Apremilast for the treatment of psoriasis and PsA. The recommended oral dose is 30 mg twice daily. Phase III clinical trial data shows that with 30 mg of Apremilast twice daily for 16 weeks, the proportion of patients reaching PASI 75 was approximately 30%, which was significantly higher than that of the placebo group, and 60% of the Apremilast group could maintain PASI 75 at 52 weeks. In addition, psoriasis on the palms and soles, nails and scalp were improved, itching symptoms were relieved, and the patient's quality of life was improved.

Reviewed the results of Phase IIb and III clinical trials of Apremilast for the treatment of nail and scalp psoriasis. In the Evaluation of the Efficacy and Safety of Apremilast in Psoriasis (ESTEEM) 1, the Nail Psoriasis Severity Index (NAPSI) of patients treated with Apremilast improved by 22.5%, 43.6% and 60.2% at weeks 16, 32 and 52, respectively, and 33.3%, 45.2% and 63% of patients reached NAPSI-50 respectively.

Headaches, diarrhea, upper respiratory tract infections, nausea, etc. have been observed in experiments. Here, the editor solemnly wants to tell all patients who are using Apremilast. It is recommended that you must take the medication correctly according to the doctor's instructions during the medication. Only by strictly following the doctor's instructions can you achieve the best effect on your own treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.